top of page
Search
  • Writer's pictureTed Ohashi

Lexaria (CSE: LXX) announces significant findings on CBD


Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced additional significant findings upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blind European human clinical study that evaluated TurboCBD™. The initial results from this study were published on August 1, 2018 and showed that the LXRP technology improved the delivery of CBD from a proprietary DehydraTECHTM powered, cannabidiol (CBD) fortified hemp oil capsule across 30, 60 and 90 minute time periods as well as through to the 6-hour mark when the study was completed.


Additional new findings from this study showed a single 90 mg dose of TurboCBD provided evidence of lower blood pressure; higher blood flow to the brain; faster delivery onset of CBD into the bloodstream; and, larger quantities of CBD within the blood compared to a single 90mg dose of generic CBD. More specifically:

  • Analysis of mean arterial blood pressure (MAP) at peak blood levels of CBD demonstrated a significant reduction in MAP compared to a placebo;

  • Cerebral perfusion was also analysed by an index of conductance in the middle cerebral artery (MCA) and revealed Lexaria’s TurboCBD™ caused the greatest increase in MCA conductance relative to both the positive control formulation and a placebo;

  • Over the six-hour study, analysis of the total area under the curve (AUC) demonstrated that TurboCBD™ resulted in a notable trend for higher levels of CBD in the bloodstream overall.

One thing I have always appreciated about LXRP’s management is their commitment to scientific research and building a portfolio of intellectual property. Each study produces additional information regarding the validity of DehydraTECHTM and adds to my confidence level. The investment conclusion is simple. If Altria (NYSE: MO) spends its $12 million researching LXRP’s technology, I believe they will find what they are looking for and if they do, they will be motivated to buy Lexaria Nicotine or could opt to pay a royalty for the use of the technology. If that happens, it will represent another major step toward unlocking some of Lexaria’s potential shareholder value.

235 views0 comments

Comments


bottom of page